Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics

Abstract

1. The pharmacokinetics of ticlopidine, a novel antithrombotic agent, have been investigated in 10 healthy volunteers dosed orally with the drug (250 mg 12 hourly for 21 days), to determine the basic pharmacokinetic parameters in humans, to investigate its accumulation during repeated administration, and to assess its effects on hepatic drug-metabolizing enzymes.

2. After the first dose, peak plasma concentrations (median 0.31, range 0.08–0.80 mg/l) were generally found at 2 h. The levels decreased rapidly to a median concentration of 0.087 mg/l by 4 h then declined to 0.022 (range<0.005–0.128) mg/l at 12 h after administration, with apparent half-lives of approx. 4 h. The median AUC value for this first dosage interval (AUC_τ) was 0.97 (range 0.41–3.49) mg h l⁻¹.

3. Pre-dose plasma concentrations indicated that steady state was reached after 5–10 days, and then remained essentially unchanged through to the end of the study. From 30 h after the final dose, drug levels declined exponentially with a median half-life of 28.8 (range≤20–50) h.

4. Following the final dose, the median peak concentration and AUC_τ were 0.99 (range 0.22–2.12)mg/l and 4.06 (range 0.90–15.2)mg h l⁻¹ respectively. Based on AUC values, the mean accumulation factor±SD was 3.73±1.14.

5. The metabolic status of subjects was assessed by administration of single doses of antipyrine (700 mg orally) 7 days before the first dose of ticlopidine and 2 days after the final dose. Treatment with ticlopidine decreased antipyrine clearance, demonstrating that it inhibited drug-metabolizing enzymes. Significant correlations (r² = 0.84, p<0.01) were found between the AUC values for ticlopidine and antipyrine, indicating that the inter-individual variation in the pharmacokinetics of ticlopidine are explained by differences in metabolic clearance.